TCR-T免疫治疗肿瘤：现状、挑战及展望

郑伟涛; 李涵泺; 胡康洪

doi:10.19401/j.cnki.1007-3639.2023.07.009

您当前的位置：

首页 >

文章列表页 >

TCR-T免疫治疗肿瘤：现状、挑战及展望

综述 | 更新时间：2025-12-31

- TCR-T免疫治疗肿瘤：现状、挑战及展望
- TCR-T immunotherapy for the treatment of solid tumor: current status, challenges and future prospects
- 中国癌症杂志 2023年33卷第7期页码：707-716
- 作者机构：
  
  湖北工业大学中德生物医学中心，工业发酵省部共建协同创新中心，国家外专局/教育部细胞调控与分子药物“111”引智基地，湖北武汉 430068
- 作者简介：
  
  [ "郑伟涛（ORCID: 0000-0002-0875-7927），博士，高级工程师。" ]
  胡康洪（ORCID: 0000-0001-8044-7889），博士，教授。
- 基金信息：
  
  湖北省重点研发项目（社会发展）(2022BCA018)
- DOI：10.19401/j.cnki.1007-3639.2023.07.009
  中图分类号： R730.51
- 收稿：2022-08-01，
  
  修回：2023-02-15，
  
  纸质出版：2023-07-30
- 稿件说明：
移动端阅览
郑伟涛, 李涵泺, 胡康洪. TCR-T免疫治疗肿瘤：现状、挑战及展望[J]. 中国癌症杂志, 2023,33(7):707-716.

Weitao ZHENG, Hanluo LI, Kanghong HU. TCR-T immunotherapy for the treatment of solid tumor: current status, challenges and future prospects[J]. China Oncology, 2023, 33(7): 707-716.
郑伟涛, 李涵泺, 胡康洪. TCR-T免疫治疗肿瘤：现状、挑战及展望[J]. 中国癌症杂志, 2023,33(7):707-716. DOI： 10.19401/j.cnki.1007-3639.2023.07.009.

Weitao ZHENG, Hanluo LI, Kanghong HU. TCR-T immunotherapy for the treatment of solid tumor: current status, challenges and future prospects[J]. China Oncology, 2023, 33(7): 707-716. DOI： 10.19401/j.cnki.1007-3639.2023.07.009.

摘要

T细胞受体工程T细胞（engineered T cell receptor-T cell，TCR-T）疗法和嵌合抗原受体T细胞（chimeric antigens receptor-T cell，CAR-T）疗法是目前过继性T细胞治疗最有效的两种方式。由于CAR仅能识别肿瘤表面的抗原，在实体瘤治疗中至今未有令人满意的结果。TCR不仅能识别肿瘤表面抗原，同时能识别胞内抗原，因此，TCR-T疗法在治疗实体瘤方面显示出前所未有的前景，成为极具潜力的治疗方式。本综述探讨了TCR-T疗法与CAR-T疗法识别癌症抗原机制的差异及当前TCR-T疗法靶向的临床靶点和不同类型的肿瘤抗原，描述了TCR-T抗肿瘤治疗的临床开发现状，并讨论了临床前评估TCR效价的标准和目前TCR-T治疗的优势、存在的局限性及可能有效的应对措施。最后，我们回顾了TCR-T治疗的现状和当前仍存在的一些挑战，强调靶向肿瘤特异性抗原的重要性，概述了结合检查点阻断治疗和溶瘤病毒等的新抗原特异性TCR-T治疗策略，以期这种联合治疗能够显著改善癌症的免疫治疗效果，并对未来TCR-T治疗根除多发性癌症提供一些思路。

Abstract

Engineered T cell receptor-T cell (TCR-T) therapy and chimeric antigen receptor-T cell (CAR-T) therapy are currently the two most effective ways of adoptive T cell therapy. Because CAR can only recognize antigens on the surface of tumors

CAR-T therapy has not yet had satisfactory results in the treatment of solid tumors. TCR can not only recognize tumor surface antigens

but also intracellular antigens. Thus TCR-T therapy has shown unprecedented promise in the treatment of solid tumors

and has become an extremely attractive treatment modality. This review described the differences between TCR-T therapy and CAR-T therapy in recognizing cancer antigens

the clinical targets and different types of tumor antigens targeted by current TCR-T therapy

the clinical development status of TCR-T antitumor therapy

and discussed the criteria for preclinical evaluation of TCR titer and the advantages

limitations and possible effective countermeasures of current TCR-T therapy. Finally

we reviewed the current status of TCR-T therapy and some of the challenges

emphasized the importance of targeting tumor-specific antigens

and outlined neoantigen-specific TCR-T treatment strategies combining checkpoint blockage therapy and oncolytic viruses

which we expect will significantly improve cancer immunotherapy and provide some clues for future TCR-T therapy to eradicate multiple types of cancer.

关键词

Keywords

references

MO Z M , DU P X , WANG G P , et al . The multi-purpose tool of tumor immunotherapy: gene-engineered T cells [J ] . J Cancer , 2017 , 8 ( 9 ): 1690 - 1703 . DOI: 10.7150/jca.18681 http://doi.org/10.7150/jca.18681

SCOTT L J . Osimertinib as first-line therapy in advanced NSCLC: a profile of its use [J ] . Drugs Ther Perspect , 2018 , 34 ( 8 ): 351 - 357 . DOI: 10.1007/s40267-018-0536-9 http://doi.org/10.1007/s40267-018-0536-9

WEBER E W , MAUS M V , MACKALL C L . The emerging landscape of immune cell therapies [J ] . Cell , 2020 , 181 ( 1 ): 46 - 62 . DOI: S0092-8674(20)30263-4 http://doi.org/S0092-8674(20)30263-4

JIANG X T , XU J , LIU M F , et al . Adoptive CD8 + T cell therapy against cancer: challenges and opportunities [J ] . Cancer Lett , 2019 , 462 : 23 - 32 . DOI: 10.1016/j.canlet.2019.07.017 http://doi.org/10.1016/j.canlet.2019.07.017 https://linkinghub.elsevier.com/retrieve/pii/S0304383519304136 https://linkinghub.elsevier.com/retrieve/pii/S0304383519304136

SALTER A I , RAJAN A , KENNEDY J J , et al . Comparative analysis of TCR and CAR signaling info rms CAR designs with superior antigen sensitivity and in vivo function [J ] . Sci Signal , 2021 , 14 ( 697 ): eabe2606 . DOI: 10.1126/scisignal.abe2606 http://doi.org/10.1126/scisignal.abe2606 https://www.science.org/doi/10.1126/scisignal.abe2606 https://www.science.org/doi/10.1126/scisignal.abe2606

XU Y Y , YANG Z Y , HORAN L H , et al . A novel antibody-TCR (AbTCR) platform combines Fab-based antigen recognition with gamma/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release [J ] . Cell Discov , 2018 , 4 : 62 . DOI: 10.1038/s41421-018-0066-6 http://doi.org/10.1038/s41421-018-0066-6

GARBER K . Driving T-cell immunotherapy to solid tumors [J ] . Nat Biotechnol , 2018 , 36 ( 3 ): 215 - 219 . DOI: 10.1038/nbt.4090 http://doi.org/10.1038/nbt.4090

CHAPUIS A G , EGAN D N , BAR M , et al . T cell receptor gene therapy targeting WT1 prevents acute myeloid leukemia relapse post-transplant [J ] . Nat Med , 2019 , 25 ( 7 ): 1064 - 1072 . DOI: 10.1038/s41591-019-0472-9 http://doi.org/10.1038/s41591-019-0472-9

BLÜTHMANN H , KISIELOW P , UEMATSU Y , et al . T-cell-specific deletion of T-cell receptor transgenes allows functional rearrangement of endogenous alpha- and beta-genes [J ] . Nature , 1988 , 334 ( 6178 ): 156 - 159 . DOI: 10.1038/334156a0 http://doi.org/10.1038/334156a0

BUONAGURO L , TAGLIAMONTE M . Selecting target antigens for cancer vaccine development [J ] . Vaccines (Basel) , 2020 , 8 ( 4 ): 615 .

ZHANG J X , WANG L Y . The emerging world of TCR-T cell trials against cancer: a systematic review [J ] . Technol Cancer Res Treat , 2019 , 18 : 1533033819831068.

ZHAO Q J , JIANG Y , XIANG S X , et al . Engineered TCR-T cell immunotherapy in anticancer precision medicine: pros and cons [J ] . Front Immunol , 2021 , 12 : 658753 . DOI: 10.3389/fimmu.2021.658753 http://doi.org/10.3389/fimmu.2021.658753 https://www.frontiersin.org/articles/10.3389/fimmu.2021.658753/full https://www.frontiersin.org/articles/10.3389/fimmu.2021.658753/full

HELLMAN L M , FOLEY K C , SINGH N K , et al . Improving T cell receptor on-target specificity via structure-guided design [J ] . Mol Ther , 2019 , 27 ( 2 ): 300 - 313 . DOI: S1525-0016(18)30594-X http://doi.org/S1525-0016(18)30594-X

TAWARA I , KAGEYAMA S , MIYAHARA Y , et al . Safety and persistence of WT1-specific T-cell receptor gene-transduced lymphocytes in patients with AML and MDS [J ] . Blood , 2017 , 130 ( 18 ): 1985 - 1994 . DOI: 10.1182/blood-2017-06-791202 http://doi.org/10.1182/blood-2017-06-791202

ROBBINS P F , MORGAN R A , FELDMAN S A , et al . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1 [J ] . J Clin Oncol , 2011 , 29 ( 7 ): 917 - 924 . DOI: 10.1200/JCO.2010.32.2537 http://doi.org/10.1200/JCO.2010.32.2537

MORGAN R A , CHINNASAMY N , ABATE-DAGA D , et al . Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy [J ] . J Immunother , 2013 , 36 ( 2 ): 133 - 151 . DOI: 10.1097/CJI.0b013e3182829903 http://doi.org/10.1097/CJI.0b013e3182829903

CAMERON B J , GERRY A B , DUKES J , et al . Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells [J ] . Sci Transl Med , 2013 , 5 ( 197 ): 197ra103 .

YE B X , STARY C M , GAO Q P , et al . Genetically modified T-cell-based adoptive immunotherapy in hematological malignancies [J ] . J Immunol Res , 2017 , 2017 : 5210459 .

LIM W A , JUNE C H . The principles of engineering immune cells to treat cancer [J ] . Cell , 2017 , 168 ( 4 ): 724 - 740 . DOI: S0092-8674(17)30064-8 http://doi.org/S0092-8674(17)30064-8

MOORE A R , ROSENBERG S C , MCCORMICK F , et al . RAS-targeted therapies: is the undruggable drugged? [J ] . Nat Rev Drug Discov , 2020 , 19 ( 8 ): 533 - 552 . DOI: 10.1038/s41573-020-0068-6 http://doi.org/10.1038/s41573-020-0068-6

WANG Q J , YU Z Y , GRIFFITH K , et al . Identification of T-cell receptors targeting KRAS -mutated human tumors [J ] . Cancer Immunol Res , 2016 , 4 ( 3 ): 204 - 214 . DOI: 10.1158/2326-6066.CIR-15-0188 http://doi.org/10.1158/2326-6066.CIR-15-0188 https://aacrjournals.org/cancerimmunolres/article/4/3/204/468486/Identification-of-T-cell-Receptors-Targeting-KRAS https://aacrjournals.org/cancerimmunolres/article/4/3/204/468486/Identification-of-T-cell-Receptors-Targeting-KRAS

MAOZ A , RENNERT G , GRUBER S B . T-cell transfer therapy targeting mutant KRAS [J ] . N Engl J Med , 2017 , 376 ( 7 ): e11 . DOI: 10.1056/NEJMc1616637 http://doi.org/10.1056/NEJMc1616637 http://www.nejm.org/doi/10.1056/NEJMc1616637 http://www.nejm.org/doi/10.1056/NEJMc1616637

DESAI J , GAN H , BARROW C , et al . Phase Ⅰ, open-label, dose-escalation/dose-expansion study of lifirafenib (BGB-283), an RAF family kinase inhibitor, in patients with solid tumors [J ] . J Clin Oncol , 2020 , 38 ( 19 ): 2140 - 2150 . DOI: 10.1200/JCO.19.02654 http://doi.org/10.1200/JCO.19.02654 https://ascopubs.org/doi/10.1200/JCO.19.02654 https://ascopubs.org/doi/10.1200/JCO.19.02654

HOOGEVEEN R C , ROBIDOUX M P , SCHWARZ T , et al . Phenotype and function of HBV-specific T cells is determined by the targeted epitope in addition to the stage of infection [J ] . Gut , 2019 , 68 ( 5 ): 893 - 904 . DOI: 10.1136/gutjnl-2018-316644 http://doi.org/10.1136/gutjnl-2018-316644

JIN B Y , CAMPBELL T E , DRAPER L M , et al . Engineered T cells targeting E7 mediate regression of human papillomavirus cancers in a murine model [J ] . JCI Insight , 2018 , 3 ( 8 ): e99488 . DOI: 10.1172/jci.insight.99488 http://doi.org/10.1172/jci.insight.99488 https://insight.jci.org/articles/view/99488 https://insight.jci.org/articles/view/99488

NAGARSHETH N B , NORBERG S M , SINKOE A L , et al . TCR-engineered T cells targeting E7 for patients with metastatic HPV-associated epithelial cancers [J ] . Nat Med , 2021 , 27 ( 3 ): 419 - 425 . DOI: 10.1038/s41591-020-01225-1 http://doi.org/10.1038/s41591-020-01225-1

DRAPER L M , KWONG M L M , GROS A , et al . Targeting of HPV-16 + epithelial cancer cells by TCR gene engineered T cells directed against E6 [J ] . Clin Cancer Res , 2015 , 21 ( 19 ): 4431 - 4439 . DOI: 10.1158/1078-0432.CCR-14-3341 http://doi.org/10.1158/1078-0432.CCR-14-3341 https://aacrjournals.org/clincancerres/article/21/19/4431/125533/Targeting-of-HPV-16-Epithelial-Cancer-Cells-by-TCR https://aacrjournals.org/clincancerres/article/21/19/4431/125533/Targeting-of-HPV-16-Epithelial-Cancer-Cells-by-TCR

JOHNSON L A , MORGAN R A , DUDLEY M E , et al . Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen [J ] . Blood , 2009 , 114 ( 3 ): 535 - 546 . DOI: 10.1182/blood-2009-03-211714 http://doi.org/10.1182/blood-2009-03-211714

PARKHURST M R , YANG J C , LANGAN R C , et al . T cells targeting carcinoembryonic antigen can mediate regression of metastatic colorectal cancer but induce severe transient colitis [J ] . Mol Ther , 2011 , 19 ( 3 ): 620 - 626 . DOI: 10.1038/mt.2010.272 http://doi.org/10.1038/mt.2010.272

LINETTE G P , STADTMAUER E A , MAUS M V , et al . Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma [J ] . Blood , 2013 , 122 ( 6 ): 863 - 871 . DOI: 10.1182/blood-2013-03-490565 http://doi.org/10.1182/blood-2013-03-490565

HONG D S , VAN TINE B A , OLSZANSKI A J , et al . Phase Ⅰ dose escalation and expansion trial to assess the safety and efficacy of ADP-A2M4 SPEAR T cells in advanced solid tumors [J ] . J Clin Oncol , 2020 , 38 ( 15_suppl ): 102 .

LAM V K , HONG D S , HEYMACH J , et al . Initial safety assessment of MAGE-A10c796 TCR T-cells in two clinical trials [J ] . J Clin Oncol , 2018 , 36 ( 15_suppl ): 3056 . DOI: 10.1200/JCO.2018.79.1400 http://doi.org/10.1200/JCO.2018.79.1400 https://ascopubs.org/doi/10.1200/JCO.2018.79.1400 https://ascopubs.org/doi/10.1200/JCO.2018.79.1400

DORAN S L , STEVANOVIĆ S , ADHIKARY S , et al . T-cell receptor gene therapy for human papillomavirus-associated epithelial cancers: a first-in-human, phase Ⅰ/Ⅱ study [J ] . J Clin Oncol , 2019 , 37 ( 30 ): 2759 - 2768 . DOI: 10.1200/JCO.18.02424 http://doi.org/10.1200/JCO.18.02424 https://ascopubs.org/doi/10.1200/JCO.18.02424 https://ascopubs.org/doi/10.1200/JCO.18.02424

DAVIS J L , THEORET M R , ZHENG Z L , et al . Development of human anti-murine T-cell receptor antibodies in both responding and nonresponding patients enrolled in TCR gene therapy trials [J ] . Clin Cancer Res , 2010 , 16 ( 23 ): 5852 - 5861 . DOI: 10.1158/1078-0432.CCR-10-1280 http://doi.org/10.1158/1078-0432.CCR-10-1280

KERNEL N N I . TCR-redirected T cells therapy in patient with HBV related HCC [J ] . Case Med Res , 2019 .[Epub ahead of print ] .

SPEAR T T , EVAVOLD B D , BAKER B M , et al . Understanding TCR affinity, antigen specificity, and cross-reactivity to improve TCR gene-modified T cells for cancer immunotherapy [J ] . Cancer Immunol Immunother , 2019 , 68 ( 11 ): 1881 - 1889 . DOI: 10.1007/s00262-019-02401-0 http://doi.org/10.1007/s00262-019-02401-0

SANDERSON J P , CROWLEY D J , WIEDERMANN G E , et al . Preclinical evaluation of an affinity-enhanced MAGE-A4-specific T-cell receptor for adoptive T-cell therapy [J ] . Oncoimmunology , 2020 , 9 ( 1 ): 1682381 . DOI: 10.1080/2162402X.2019.1682381 http://doi.org/10.1080/2162402X.2019.1682381 https://www.tandfonline.com/doi/full/10.1080/2162402X.2019.1682381 https://www.tandfonline.com/doi/full/10.1080/2162402X.2019.1682381

KHONG H T , WANG Q J , ROSENBERG S A . Identification of multiple antigens recognized by tumor-infiltrating lymphocytes from a single patient: tumor escape by antigen loss and loss of MHC expression [J ] . J Immunother , 2004 , 27 ( 3 ): 184 - 190 . DOI: 10.1097/00002371-200405000-00002 http://doi.org/10.1097/00002371-200405000-00002

NATHAN P , HASSEL J C , RUTKOWSKI P , et al . Overall survival benefit with tebentafusp in metastatic uveal melanoma [J ] . N Engl J Med , 2021 , 385 ( 13 ): 1196 - 1206 . DOI: 10.1056/NEJMoa2103485 http://doi.org/10.1056/NEJMoa2103485 http://www.nejm.org/doi/10.1056/NEJMoa2103485 http://www.nejm.org/doi/10.1056/NEJMoa2103485

WALKER A J , MAJZNER R G , ZHANG L , et al . Tumor antigen and receptor densities regulate efficacy of a chimeric antigen receptor targeting anaplastic lymphoma kinase [J ] . Mol Ther , 2017 , 25 ( 9 ): 2189 - 2201 . DOI: S1525-0016(17)30270-8 http://doi.org/S1525-0016(17)30270-8

ROBINSON J , HALLIWELL J A , HAYHURST J D , et al . The IPD and IMGT/HLA database: allele variant databases [J ] . Nucleic Acids Res , 2015 , 43 (Database issue): D423 - D431 . DOI: 10.1093/nar/gku1161 http://doi.org/10.1093/nar/gku1161 http://academic.oup.com/nar/article/43/D1/D423/2438496/The-IPD-and-IMGTHLA-database-allele-variant http://academic.oup.com/nar/article/43/D1/D423/2438496/The-IPD-and-IMGTHLA-database-allele-variant

GONZALEZ-GALARZA F F , MCCABE A , SANTOS E J M D , et al . Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools [J ] . Nucleic Acids Res , 2020 , 48 ( D1 ): D783 - D788 .

GARETTO S , SARDI C , MARTINI E , et al . Tailored chemokine receptor modification improves homing of adoptive therapy T cells in a spontaneous tumor model [J ] . Oncotarget , 2016 , 7 ( 28 ): 43010 - 43026 . DOI: 10.18632/oncotarget.9280 http://doi.org/10.18632/oncotarget.9280

IDORN M , SKADBORG S K , KELLERMANN L , et al . Chemokine receptor engineering of T cells with CXCR2 improves homing towards subcutaneous human melanomas in xenograft mouse model [J ] . Oncoimmunology , 2018 , 7 ( 8 ): e1450715 .

HU J M , SUN C , BERNATCHEZ C , et al . T-cell homing therapy for reducing regulatory T cells and preserving effector T-cell function in large solid tumors [J ] . Clin Cancer Res , 2018 , 24 ( 12 ): 2920 - 2934 . DOI: 10.1158/1078-0432.CCR-17-1365 http://doi.org/10.1158/1078-0432.CCR-17-1365

ADACHI K , KANO Y , NAGAI T , et al . IL-7 and CCL19 expression in CAR-T cells improves immune cell infiltration and CAR-T cell survival in the tumor [J ] . Nat Biotechnol , 2018 , 36 ( 4 ): 346 - 351 . DOI: 10.1038/nbt.4086 http://doi.org/10.1038/nbt.4086

FRAIETTA J A , LACEY S F , ORLANDO E J , et al . Author correction: determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia [J ] . Nat Med , 2021 , 27 ( 3 ): 561 . DOI: 10.1038/s41591-021-01248-2 http://doi.org/10.1038/s41591-021-01248-2

BECHMAN N , MAHER J . Lymphodepletion strategies to potentiate adoptive T-cell immunotherapy-what are we doing; where are we going ?[J ] . Expert Opin Biol Ther , 2021 , 21 ( 5 ): 627 - 637 . DOI: 10.1080/14712598.2021.1857361 http://doi.org/10.1080/14712598.2021.1857361 https://www.tandfonline.com/doi/full/10.1080/14712598.2021.1857361 https://www.tandfonline.com/doi/full/10.1080/14712598.2021.1857361

CHEN J , SUN H W , YANG Y Y , et al . Reprogramming immunosuppressive myeloid cells by activated T cells promotes the response to anti-PD-1 therapy in colorectal cancer [J ] . Signal Transduct Target Ther , 2021 , 6 ( 1 ): 4 .

KIM J , KANG S , KIM K W , et al . Nanoparticle delivery of recombinant IL-2 (BALLkine-2) achieves durable tumor control with less systemic adverse effects in cancer immunotherapy [J ] . Biomaterials , 2022 , 280 : 121257 . DOI: 10.1016/j.biomaterials.2021.121257 http://doi.org/10.1016/j.biomaterials.2021.121257 https://linkinghub.elsevier.com/retrieve/pii/S0142961221006141 https://linkinghub.elsevier.com/retrieve/pii/S0142961221006141

SAKAI T , TERAKURA S , MIYAO K , et al . Artificial T cell adaptor molecule-transduced TCR-T cells demonstrated improved proliferation only when transduced in a higher intensity [J ] . Mol Ther Oncolytics , 2020 , 18 : 613 - 622 . DOI: 10.1016/j.omto.2020.08.014 http://doi.org/10.1016/j.omto.2020.08.014 https://linkinghub.elsevier.com/retrieve/pii/S2372770520301315 https://linkinghub.elsevier.com/retrieve/pii/S2372770520301315

ROTH T L , LI P J , BLAESCHKE F , et al . Pooled knockin targeting for genome engineering of cellular immunotherapies [J ] . Cell , 2020 , 181 ( 3 ): 728 - 744 .e21. DOI: S0092-8674(20)30332-9 http://doi.org/S0092-8674(20)30332-9

MARTINEZ M , MOON E K . CAR T cells for solid tumors: New strategies for finding, infiltrating, and surviving in the tumor microenvironment [J ] . Front Immunol , 2019 , 10 : 128 . DOI: 10.3389/fimmu.2019.00128 http://doi.org/10.3389/fimmu.2019.00128

NALAWADE S A , SHAFER P , BAJGAIN P , et al . Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer [J ] . J Immunother Cancer , 2021 , 9 ( 11 ): e003237 . DOI: 10.1136/jitc-2021-003237 http://doi.org/10.1136/jitc-2021-003237 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-003237 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-003237

LIN S H , CHENG L , YE W , et al . Chimeric CTLA4-CD28-CD3z T cells potentiate antitumor activity against CD80/CD86-positive B cell malignancies [J ] . Front Immunol , 2021 , 12 : 642528 . DOI: 10.3389/fimmu.2021.642528 http://doi.org/10.3389/fimmu.2021.642528 https://www.frontiersin.org/articles/10.3389/fimmu.2021.642528/full https://www.frontiersin.org/articles/10.3389/fimmu.2021.642528/full

NEWICK K , O'BRIEN S , MOON E , et al . CAR T cell therapy for solid tumors [J ] . Annu Rev Med , 2017 , 68 : 139 - 152 . DOI: 10.1146/annurev-med-062315-120245 http://doi.org/10.1146/annurev-med-062315-120245

D’ALOIA M M , ZIZZARI I G , SACCHETTI B , et al . CAR-T cells: the long and winding road to solid tumors [J ] . Cell Death Dis , 2018 , 9 ( 3 ): 282 . DOI: 10.1038/s41419-018-0278-6 http://doi.org/10.1038/s41419-018-0278-6

ZHANG B L , QIN D Y , MO Z M , et al . Hurdles of CAR-T cell-based cancer immunotherapy directed against solid tumors [J ] . Sci China Life Sci , 2016 , 59 ( 4 ): 340 - 348 . DOI: 10.1007/s11427-016-5027-4 http://doi.org/10.1007/s11427-016-5027-4 http://link.springer.com/10.1007/s11427-016-5027-4 http://link.springer.com/10.1007/s11427-016-5027-4

YE B X , SMERIN D , GAO Q P , et al . High-throughput sequencing of the immune repertoire in oncology: applications for clinical diagnosis, monitoring, and immunotherapies [J ] . Cancer Lett , 2018 , 416 : 42 - 56 . DOI: S0304-3835(17)30789-9 http://doi.org/S0304-3835(17)30789-9

CHEN F J , ZOU Z Y , DU J , et al . Neoantigen identification strategies enable personalized immunotherapy in refractory solid tumors [J ] . J Clin Invest , 2019 , 129 ( 5 ): 2056 - 2070 . DOI: 10.1172/JCI99538 http://doi.org/10.1172/JCI99538

JOGLEKAR A V , LEONARD M T , JEPPSON J D , et al . T cell antigen discovery via signaling and antigen-presenting bifunctional receptors [J ] . Nat Methods , 2019 , 16 ( 2 ): 191 - 198 . DOI: 10.1038/s41592-018-0304-8 http://doi.org/10.1038/s41592-018-0304-8

CHEN X J , PONCETTE L , BLANKENSTEIN T . Human TCR-MHC coevolution after divergence from mice includes increased nontemplate-encoded CDR3 diversity [J ] . J Exp Med , 2017 , 214 ( 11 ): 3417 - 3433 . DOI: 10.1084/jem.20161784 http://doi.org/10.1084/jem.20161784 https://rupress.org/jem/article/214/11/3417/42268/Human-TCR-MHC-coevolution-after-divergence-from https://rupress.org/jem/article/214/11/3417/42268/Human-TCR-MHC-coevolution-after-divergence-from

KRSHNAN L , PARK S , IM W , et al . A conserved αβ transmembrane interface forms the core of a compact T-cell receptor-CD3 structure within the membrane [J ] . Proc Natl Acad Sci U S A , 2016 , 113 ( 43 ): E6649 - E6658 .

KNIES D , KLOBUCH S , XUE S A , et al . An optimized single chain TCR scaffold relying on the assembly with the native CD3-complex prevents residual mispairing with endogenous TCRs in human T-cells [J ] . Oncotarget , 2016 , 7 ( 16 ): 21199 - 21221 . DOI: 10.18632/oncotarget.8385 http://doi.org/10.18632/oncotarget.8385

ARMISTEAD P M . Cellular therapy against public neoantigens [J ] . J Clin Invest , 2019 , 129 ( 2 ): 506 - 508 . DOI: 10.1172/JCI126116 http://doi.org/10.1172/JCI126116

LU Y C , ZHENG Z L , LOWERY F J , et al . Direct identification of neoantigen-specific TCRs from tumor specimens by high-throughput single-cell sequencing [J ] . J Immunother Cancer , 2021 , 9 ( 7 ): e002595 . DOI: 10.1136/jitc-2021-002595 http://doi.org/10.1136/jitc-2021-002595 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-002595 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2021-002595

LI S R , HUO F Y , WANG H Q , et al . Recent advances in porous nanomaterials-based drug delivery systems for cancer immunotherapy [J ] . J Nanobiotechnology , 2022 , 20 ( 1 ): 277 . DOI: 10.1186/s12951-022-01489-4 http://doi.org/10.1186/s12951-022-01489-4

CADILHA B L , BENMEBAREK M R , DORMAN K , et al . Combined tumor-directed recruitment and protection from immune suppression enable CAR T cell efficacy in solid tumors [J ] . Sci Adv , 2021 , 7 ( 24 ): eabi5781 . DOI: 10.1126/sciadv.abi5781 http://doi.org/10.1126/sciadv.abi5781 https://www.science.org/doi/10.1126/sciadv.abi5781 https://www.science.org/doi/10.1126/sciadv.abi5781

EVGIN L , KOTTKE T , TONNE J , et al . Oncolytic virus-mediated expansion of dual-specific CAR T cells improves efficacy against solid tumors in mice [J ] . Sci Transl Med , 2022 , 14 ( 640 ): eabn2231 . DOI: 10.1126/scitranslmed.abn2231 http://doi.org/10.1126/scitranslmed.abn2231 https://www.science.org/doi/10.1126/scitranslmed.abn2231 https://www.science.org/doi/10.1126/scitranslmed.abn2231

PARKHURST M , GROS A , PASETTO A , et al . Isolation of T-cell receptors specifically reactive with mutated tumor-associated antigens from tumor-infiltrating lymphocytes based on CD137 expression [J ] . Clin Cancer Res , 2017 , 23 ( 10 ): 2491 - 2505 . DOI: 10.1158/1078-0432.CCR-16-2680 http://doi.org/10.1158/1078-0432.CCR-16-2680

MARCU A , BICHMANN L , KUCHENBECKER L , et al . HLA Ligand Atlas: a benign reference of HLA-presented peptides to improve T-cell-based cancer immunotherapy [J ] . J Immunother Cancer , 2021 , 9 ( 4 ): e002071 . DOI: 10.1136/jitc-2020-002071 http://doi.org/10.1136/jitc-2020-002071 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2020-002071 https://jitc.bmj.com/lookup/doi/10.1136/jitc-2020-002071

HU Z D , ZHU L Y , WANG J , et al . Immune signature of enhanced functional avidity CD8 + T cells in vivo induced by vaccinia vectored vaccine [J ] . Sci Rep , 2017 , 7 : 41558 . DOI: 10.1038/srep41558 http://doi.org/10.1038/srep41558

ALBA J , D‘ABRAMO M . The full model of the pMHC-TCR-CD3 complex: a structural and dynamical characterization of bound and unbound states [J ] . Cells , 2022 , 11 ( 4 ): 668 . DOI: 10.3390/cells11040668 http://doi.org/10.3390/cells11040668 https://www.mdpi.com/2073-4409/11/4/668 https://www.mdpi.com/2073-4409/11/4/668

HE W H , CAO Z L , MAO F F , et al . Modification of three amino acids in sodium taurocholate cotransporting polypeptide renders mice susceptible to infection with hepatitis D virus in vivo [J ] . J Virol , 2016 , 90 ( 19 ): 8866 - 8874 . DOI: 10.1128/JVI.00901-16 http://doi.org/10.1128/JVI.00901-16 https://journals.asm.org/doi/10.1128/JVI.00901-16 https://journals.asm.org/doi/10.1128/JVI.00901-16

CAO Y Q , LU W Y , SUN R , et al . Anti-CD19 chimeric antigen receptor T cells in combination with nivolumab are safe and effective against relapsed/refractory B-cell non-Hodgkin lymphoma [J ] . Front Oncol , 2019 , 9 : 767 . DOI: 10.3389/fonc.2019.00767 http://doi.org/10.3389/fonc.2019.00767

浏览量

2318

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

靶向治疗及免疫治疗联合化疗为产AFP阳性结肠癌患者带来显著获益1例病例报告并文献复习

MYC通过靶向CD47促进前列腺癌增殖和转移的机制研究

局部晚期头颈部鳞状细胞癌免疫治疗MDT专家共识（2025年版）

转移性结直肠癌三线治疗的研究现状及进展

鞘内注射培美曲塞联合程序性死亡蛋白-1抑制剂治疗实体瘤脑膜转移的Ⅰ期临床研究